Cara Therapeutics, Inc.
CARA Real Time Price USDRecent trades of CARA by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by CARA's directors and management
Government lobbying spending instances
-
$20,000 Jan 22, 2024 Issue: Medicare/Medicaid
-
$20,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$10,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$12,000 Jul 20, 2022 Issue: Medicare/Medicaid
-
$15,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$16,000 Feb 09, 2022 Issue: Medicare/Medicaid
-
$12,500 Oct 20, 2021 Issue: Medicare/Medicaid
-
$23,750 Jul 21, 2021 Issue: Medicare/Medicaid
-
$9,500 Apr 20, 2021 Issue: Medicare/Medicaid
-
$9,000 Oct 19, 2020 Issue: Medicare/Medicaid
-
$7,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$7,000 Apr 20, 2020 Issue: Medicare/Medicaid
-
$13,000 Oct 26, 2019 Issue: Medicare/Medicaid
-
$5,000 Jul 26, 2019 Issue: Medicare/Medicaid
-
$20,000 Apr 19, 2019 Issue: Medicare/Medicaid
-
$12,000 Jan 22, 2019 Issue: Medicare/Medicaid
-
$15,000 Oct 22, 2018 Issue: Medicare/Medicaid
Estimated quarterly lobbying spending
New patents grants
No new patents for this ticker
U.S. Patents DashboardFederal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of CARA in WallStreetBets Daily Discussion
Recent insights relating to CARA
Recent picks made for CARA stock on CNBC
ETFs with the largest estimated holdings in CARA
Shareholder
|
Shares Held
|
---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CARA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.